How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, sex, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about marstacimab

Anticipated marketing authorisation indication

2.1

Marstacimab (Hympavzi, Pfizer) does not yet have a marketing authorisation in Great Britain. It received a marketing authorisation by The European Commission "for routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with: severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors or severe haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor VIX inhibitors.

Dosage in the marketing authorisation

2.2

The dosage schedule will be available in the summary of product characteristics for marstacimab.

Price

2.3

The list price of marstacimab is confidential until published by the Department for Health and Social Care.

2.4

The company has a commercial arrangement, which would have applied if marstacimab had been recommended.